Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Septerna to Participate in Upcoming Investor Conferences

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Maze Therapeutics Announces Appointments to Its Board of Directors

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Tango Therapeutics Announces Executive Chair Transition

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Clasp Therapeutics Publishes Preclinical Data on CLSP-1025, the First Clinical-Stage T-Cell Engager Targeting an Intracellular Driver Mutation, in Clinical Cancer Research

ARTBIO Appoints Jonathan Freeman Interim Chief Executive Officer

Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Trace Neuroscience Initiates Global Clinical Development Program for TRCN-1023, an Antisense Oligonucleotide Designed to Restore UNC13A Function for the Treatment of ALS

Experienced Neuropsychiatry Drug Development Leader Joins Syremis’ Executive Team Ahead of Key Pipeline Milestones

Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

Tango Therapeutics Announces Proposed $500 Million Public Offering

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers

Maze Therapeutics Announces $150 Million Registered Offering

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

Clasp Therapeutics Unveils First-in-Class KRas T Cell Engager CLSP-5282 at AACR 2026

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Novartis to acquire Synnovation Therapeutics’s pan-mutant selective PI3Kα inhibitor program

Azalea Therapeutics Highlights Nature Publication Demonstrating In Vivo Site-Specific TRAC-CAR T Cell Engineering

Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results